RECMA Bio
Robotic Enabled Cellular Matrix Application
Health Tech & Life Sciences
Non Active, Oct 2024 ceased to operate
Company Overview
Snapshot
Founded in October 2022, RECMA Bio operates with 1–10 employees. The company is currently in the Pre-Funding stage and ceased operations in October 2024.
Business overview
RECMA Bio is focused on addressing unmet needs in tissue regeneration by developing a robotic system for in-situ bioprinting. The company integrates biomaterial sciences, tissue engineering, 3D bioprinting, and robotics to harness the body's natural healing capabilities. RECMA Bio operates within the Health Tech & Life Sciences sector, specifically targeting areas like Medical Devices, Pharma & Medical Biotechnology, and Biomaterials & Tissue Engineering.
Company Intelligence Q&A
- What is RECMA Bio's primary focus?
- RECMA Bio's primary focus is on resolving challenging unmet needs in medicine, specifically in tissue regeneration, through the development of a robotic system for in-situ bioprinting.
- What technologies does RECMA Bio combine in its approach?
- RECMA Bio combines biomaterial sciences, tissue engineering, 3D bioprinting, and robotics to develop its in-situ bioprinting system.
- When was RECMA Bio founded?
- RECMA Bio was founded in October 2022.
- What is the current operational status of RECMA Bio?
- RECMA Bio ceased to operate in October 2024.
- In which sector does RECMA Bio primarily operate?
- RECMA Bio primarily operates in the Health Tech & Life Sciences sector, with a focus on Medical Devices, Pharma & Medical Biotechnology, and Biomaterials & Tissue Engineering.